Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01012804|
Recruitment Status : Withdrawn
First Posted : November 13, 2009
Last Update Posted : March 24, 2011
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is looking at biomarkers in tissue samples from patients with metastatic colon cancer.
|Condition or disease||Intervention/treatment|
|Colorectal Cancer||Genetic: western blotting Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
- Determine the effect of surgical resection, in terms of physiological stress, on levels of tumor markers such as protein kinase A (PKA) expression in patients with metastatic colon cancer.
- Estimate variation among patients of baseline tumor markers in tumor tissue and sera.
- Correlate markers in tumor tissues with that in sera in these patients.
- Establish a tissue bank of these specimens for future studies.
OUTLINE: Biopsy and surgical specimens are obtained before and during standard surgery (patients may have had tumor tissue obtained before study entry and stored). Serum samples and tumor tissue are analyzed by immunohistochemistry and western blot. Tumor markers (such as PKA expression) are determined and marker levels are measured in serum samples and tissues.
PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Assessment of Variation of PKA and Other Molecular Markers in Patients Undergoing Resection of Colon Cancer Metastases|
|Study Start Date :||January 2000|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01012804
|United States, District of Columbia|
|Lombardi Comprehensive Cancer Center at Georgetown University Medical Center|
|Washington, District of Columbia, United States, 20007|
|Study Chair:||John L. Marshall, MD||Lombardi Comprehensive Cancer Center|